Revenue
0 USD
2026-05-31 · USD
Exact inputs and evidence
- Revenue: 0 USD Source
Fundies. English
LEXARIA BIOSCIENCE CORP.
EDGARAnnual consolidated revenue for 2025: about USD 705.9K, using the latest reported figures. The previous period, 2024, was about USD 464.3K.
Latest quarter
Operating cash flow
-1.64 million USD
2026-05-31 · USD
Free cash flow
-1.64 million USD
2026-05-31 · USD
- Cash and cash equivalents
- 3.5 million USD Source
Exact value
3500000 USD
- Long-term debt including current maturities
- Not available
- Shares outstanding
- 24.8 million shares Source
Exact value
24787446 shares
Reported share-count change
27.38% · 5.33 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Trailing twelve months
The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.
Revenue
194 thousand USD
2025-06-01 – 2026-05-31
Net income
-7.73 million USD
2025-06-01 – 2026-05-31
Exact inputs and evidence
Operating cash flow
-7.43 million USD
2025-06-01 – 2026-05-31
Exact inputs and evidence
- Operating cash flow: -10450387 USD · 2024-09-01 – 2025-08-31 Source
- Operating cash flow: -7807889 USD · 2024-09-01 – 2025-05-31 Source
- Operating cash flow: -984098 USD · 2025-09-01 – 2025-11-30 Source
- Operating cash flow: -3147970 USD · 2025-09-01 – 2026-02-28 Source
- Operating cash flow: -984098 USD · 2025-09-01 – 2025-11-30 Source
- Operating cash flow: -4782990 USD · 2025-09-01 – 2026-05-31 Source
- Operating cash flow: -3147970 USD · 2025-09-01 – 2026-02-28 Source
Capital expenditure
40.8 thousand USD
2025-06-01 – 2026-05-31
Exact inputs and evidence
- Capital expenditure: 24646 USD · 2024-09-01 – 2025-08-31 Source
- Capital expenditure: 24645 USD · 2024-09-01 – 2025-05-31 Source
- Capital expenditure: 0 USD · 2025-09-01 – 2025-11-30 Source
- Capital expenditure: 40816 USD · 2025-09-01 – 2026-02-28 Source
- Capital expenditure: 0 USD · 2025-09-01 – 2025-11-30 Source
- Capital expenditure: 40816 USD · 2025-09-01 – 2026-05-31 Source
- Capital expenditure: 40816 USD · 2025-09-01 – 2026-02-28 Source
Free cash flow
-7.47 million USD
2025-06-01 – 2026-05-31
Exact inputs and evidence
- Operating cash flow: -10450387 USD · 2024-09-01 – 2025-08-31 Source
- Operating cash flow: -7807889 USD · 2024-09-01 – 2025-05-31 Source
- Operating cash flow: -984098 USD · 2025-09-01 – 2025-11-30 Source
- Operating cash flow: -3147970 USD · 2025-09-01 – 2026-02-28 Source
- Operating cash flow: -984098 USD · 2025-09-01 – 2025-11-30 Source
- Operating cash flow: -4782990 USD · 2025-09-01 – 2026-05-31 Source
- Operating cash flow: -3147970 USD · 2025-09-01 – 2026-02-28 Source
- Capital expenditure: 24646 USD · 2024-09-01 – 2025-08-31 Source
- Capital expenditure: 24645 USD · 2024-09-01 – 2025-05-31 Source
- Capital expenditure: 0 USD · 2025-09-01 – 2025-11-30 Source
- Capital expenditure: 40816 USD · 2025-09-01 – 2026-02-28 Source
- Capital expenditure: 0 USD · 2025-09-01 – 2025-11-30 Source
- Capital expenditure: 40816 USD · 2025-09-01 – 2026-05-31 Source
- Capital expenditure: 40816 USD · 2025-09-01 – 2026-02-28 Source
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-10-02.
Financial data available through: 2025-08-31.
Coverage by financial measure
- Revenue: 8 of 11 periods available· newest 2025-08-31
- Operating income: 8 of 11 periods available· newest 2025-08-31
- Net income: 11 of 11 periods available· newest 2025-08-31
- Operating cash flow: 11 of 11 periods available· newest 2025-08-31
- Capital expenditure: 9 of 11 periods available· newest 2025-08-31
- Total assets: 8 of 11 periods available· newest 2025-08-31
- Total liabilities: 8 of 11 periods available· newest 2025-08-31
- Current assets: 8 of 11 periods available· newest 2025-08-31
- Current liabilities: 8 of 11 periods available· newest 2025-08-31
- Cash and cash equivalents: 5 of 11 periods available· newest 2022-08-31
- long term debt: No compatible figures in this window
- Shares outstanding: 8 of 11 periods available· newest 2025-08-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Revenue
+52%Prior period
USD 464,278
–
Current period
USD 705,923
–
Exact inputs and evidence
705923 − 464278 = 241645 USD
464278 USD · 2023-09-01 – 2024-08-31
Inspect prior input Prior source705923 USD · 2024-09-01 – 2025-08-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 6.11 millionPrior period
−USD 5.8 million
–
Current period
−USD 11.9 million
–
Exact inputs and evidence
-11901841 − -5795345 = -6106496 USD
-5795345 USD · 2023-09-01 – 2024-08-31
Inspect prior input Prior source-11901841 USD · 2024-09-01 – 2025-08-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 5.49 millionPrior period
−USD 4.96 million
–
Current period
−USD 10.45 million
–
Exact inputs and evidence
-10450387 − -4959003 = -5491384 USD
-4959003 USD · 2023-09-01 – 2024-08-31
Inspect prior input Prior source-10450387 USD · 2024-09-01 – 2025-08-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-42.7%Prior period
USD 43,014
–
Current period
USD 24,646
–
Exact inputs and evidence
24646 − 43014 = -18368 USD
43014 USD · 2023-09-01 – 2024-08-31
Inspect prior input Prior source24646 USD · 2024-09-01 – 2025-08-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
2025 2024-09-01 – 2025-08-31
- Revenue USD 705,923 100% of revenue
- Cost of revenue USD 2,720 0.4% of revenue
- Operating expenses USD 12.58 million 1,783% of revenue
- Operating income −USD 11.88 million −1,683% of revenue
- Tax, interest and other Derived USD 21,104 3% of revenue
- Net income −USD 11.9 million −1,686% of revenue
Cash
- Operating cash flow −USD 10.45 million −1,480% of revenue
- Capital expenditure USD 24,646 3.5% of revenue
- Free cash flow Derived −USD 10.48 million −1,484% of revenue
Share of revenue by period
- Net income
- Tax, interest and other
- Operating costs
- 2018 Not shown: operating income or net income is not reported.
- 2019 Not shown: operating income or net income is not reported.
- 2020 Not shown: operating income or net income is not reported.
- 2021 Operating loss: operating costs were 887% of revenue.
- 2022 Operating loss: operating costs were 2,692% of revenue.
- 2023 Operating loss: operating costs were 2,989% of revenue.
- 2024 Operating loss: operating costs were 1,339% of revenue.
- 2025 Operating loss: operating costs were 1,783% of revenue.
Values and sources
| Period | Revenue | Operating costs | Operating income | Tax, interest and other | Net income | Free cash flow | Source |
|---|---|---|---|---|---|---|---|
| 2018 2017-09-01 – 2018-08-31 | 433287 | Unavailable | Unavailable | Unavailable | 6600000 | Unavailable | Source
|
| 2019 2018-09-01 – 2019-08-31 | 222610 | Unavailable | Unavailable | Unavailable | 4100000 | -3651738 Derived | Source
|
| 2020 2019-09-01 – 2020-08-31 | 314793 | Unavailable | Unavailable | Unavailable | -4084613 | -2618785 Derived | Source
|
| 2021 2020-09-01 – 2021-08-31 | 722738 | 6409590 Derived | -5686852 | -1659846 Derived | -4027006 | Unavailable | Source
|
| 2022 2021-09-01 – 2022-08-31 | 255397 | 6874436 Derived | -6619039 | 650285 Derived | -7269324 | -4928531 Derived | Source
|
| 2023 2022-09-01 – 2023-08-31 | 226208 | 6760230 Derived | -6534022 | 130877 Derived | -6664899 | -5914985 Derived | Source
|
| 2024 2023-09-01 – 2024-08-31 | 464278 | 6217408 Derived | -5753130 | 42215 Derived | -5795345 | -5002017 Derived | Source
|
| 2025 2024-09-01 – 2025-08-31 | 705923 | 12586660 Derived | -11880737 | 21104 Derived | -11901841 | -10475033 Derived | Source
|
Amounts are exact, in USD.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
USD 705.9K 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2018 | Revenue | 433287 |
|
| 2019 | Revenue | 222610 |
|
| 2020 | Revenue | 314793 |
|
| 2021 | Revenue | 722738 |
|
| 2022 | Revenue | 255397 |
|
| 2023 | Revenue | 226208 |
|
| 2024 | Revenue | 464278 |
|
| 2025 | Revenue | 705923 |
|
Revenue growth
Change in revenue from the same financial period one year earlier.
52% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2018 | Year over year | No prior comparable period |
|
| 2019 | Year over year | -48.6% |
|
| 2020 | Year over year | 41.4% |
|
| 2021 | Year over year | 129.6% |
|
| 2022 | Year over year | -64.7% |
|
| 2023 | Year over year | -11.4% |
|
| 2024 | Year over year | 105.2% |
|
| 2025 | Year over year | 52% |
|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
Operating margin -1,683% 2025
Net margin -1,686% 2025
Free cash flow margin -1,483.9% 2025
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2018-08-31 | Operating margin | Not reported |
|
| 2019-08-31 | Operating margin | Not reported |
|
| 2020-08-31 | Operating margin | Not reported |
|
| 2021 | Operating margin | -786.8% |
|
| 2022 | Operating margin | -2,591.7% |
|
| 2023 | Operating margin | -2,888.5% |
|
| 2024 | Operating margin | -1,239.2% |
|
| 2025 | Operating margin | -1,683% |
|
| 2018 | Net margin | 1,523.2% |
|
| 2019 | Net margin | 1,841.8% |
|
| 2020 | Net margin | -1,297.6% |
|
| 2021 | Net margin | -557.2% |
|
| 2022 | Net margin | -2,846.3% |
|
| 2023 | Net margin | -2,946.4% |
|
| 2024 | Net margin | -1,248.2% |
|
| 2025 | Net margin | -1,686% |
|
| 2018 | Free cash flow margin | Not reported |
|
| 2019 | Free cash flow margin | -1,640.4% |
|
| 2020 | Free cash flow margin | -831.9% |
|
| 2021 | Free cash flow margin | Not reported |
|
| 2022 | Free cash flow margin | -1,929.8% |
|
| 2023 | Free cash flow margin | -2,614.8% |
|
| 2024 | Free cash flow margin | -1,077.4% |
|
| 2025 | Free cash flow margin | -1,483.9% |
|
Operating cash flow
Cash generated by the company’s normal business operations.
USD -10.5M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2018 | Operating cash flow | -2517979 |
|
| 2019 | Operating cash flow | -3005555 |
|
| 2020 | Operating cash flow | -2618785 |
|
| 2021 | Operating cash flow | -3989678 |
|
| 2022 | Operating cash flow | -4879339 |
|
| 2023 | Operating cash flow | -5881237 |
|
| 2024 | Operating cash flow | -4959003 |
|
| 2025 | Operating cash flow | -10450387 |
|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
USD -10.5M 2025
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|---|---|---|
| 2018 | Free cash flow | Unavailable |
|
| 2019 | Free cash flow | -3651738 |
|
| 2020 | Free cash flow | -2618785 |
|
| 2021 | Free cash flow | Unavailable |
|
| 2022 | Free cash flow | -4928531 |
|
| 2023 | Free cash flow | -5914985 |
|
| 2024 | Free cash flow | -5002017 |
|
| 2025 | Free cash flow | -10475033 |
|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
37.7% 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2018 | Liabilities / assets | 1.8% |
|
| 2019 | Liabilities / assets | 6.9% |
|
| 2020 | Liabilities / assets | 12.2% |
|
| 2021 | Liabilities / assets | 1.5% |
|
| 2022 | Liabilities / assets | 2.6% |
|
| 2023 | Liabilities / assets | 13.1% |
|
| 2024 | Liabilities / assets | 13.6% |
|
| 2025 | Liabilities / assets | 37.7% |
|
Current assets to current liabilities
Current assets divided by current liabilities.
2.32× 2025
Values and sources
| Period | Series | Value | Source evidence |
|---|---|---|---|
| 2018 | Current assets / current liabilities | 52.34× |
|
| 2019 | Current assets / current liabilities | 9.86× |
|
| 2020 | Current assets / current liabilities | 8.53× |
|
| 2021 | Current assets / current liabilities | 81.18× |
|
| 2022 | Current assets / current liabilities | 35.96× |
|
| 2023 | Current assets / current liabilities | 8.03× |
|
| 2024 | Current assets / current liabilities | 7.18× |
|
| 2025 | Current assets / current liabilities | 2.32× |
|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2016 2015-09-01 – 2016-08-31 | −USD 1.28 million Exact valueExact value: -1277249 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 660,856 Exact valueExact value: -660856 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 3,094 Exact valueExact value: 3094 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 663,950 Calculation and evidence-660856 − 3094 USD Exact free cash flow: -663950 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2017 2016-09-01 – 2017-08-31 | −USD 1.93 million Exact valueExact value: -1929465 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.55 million Exact valueExact value: -1545909 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 1.55 million Calculation and evidence-1545909 − 0 USD Exact free cash flow: -1545909 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2018 2017-09-01 – 2018-08-31 | USD 6.6 million Exact valueExact value: 6600000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.52 million Exact valueExact value: -2517979 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2019 2018-09-01 – 2019-08-31 | USD 4.1 million Exact valueExact value: 4100000 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.01 million Exact valueExact value: -3005555 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 646,183 Exact valueExact value: 646183 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.65 million Calculation and evidence-3005555 − 646183 USD Exact free cash flow: -3651738 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2019-09-01 – 2020-08-31 | −USD 4.08 million Exact valueExact value: -4084613 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.62 million Exact valueExact value: -2618785 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: 0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 2.62 million Calculation and evidence-2618785 − 0 USD Exact free cash flow: -2618785 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2020-09-01 – 2021-08-31 | −USD 4.03 million Exact valueExact value: -4027006 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 3.99 million Exact valueExact value: -3989678 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | Unavailable Not reported for this period. | Unavailable Free cash flow cannot be calculated because Capital expenditure is unavailable for this period. |
| 2022 2021-09-01 – 2022-08-31 | −USD 7.27 million Exact valueExact value: -7269324 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.88 million Exact valueExact value: -4879339 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 49,192 Exact valueExact value: 49192 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.93 million Calculation and evidence-4879339 − 49192 USD Exact free cash flow: -4928531 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2022-09-01 – 2023-08-31 | −USD 6.66 million Exact valueExact value: -6664899 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.88 million Exact valueExact value: -5881237 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 33,748 Exact valueExact value: 33748 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5.91 million Calculation and evidence-5881237 − 33748 USD Exact free cash flow: -5914985 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2023-09-01 – 2024-08-31 | −USD 5.8 million Exact valueExact value: -5795345 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 4.96 million Exact valueExact value: -4959003 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 43,014 Exact valueExact value: 43014 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 5 million Calculation and evidence-4959003 − 43014 USD Exact free cash flow: -5002017 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2024-09-01 – 2025-08-31 | −USD 11.9 million Exact valueExact value: -11901841 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.45 million Exact valueExact value: -10450387 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 24,646 Exact valueExact value: 24646 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.48 million Calculation and evidence-10450387 − 24646 USD Exact free cash flow: -10475033 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
114 filings · 4,054 latest values · 4,060 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001348362, 1348362, LEXX, edgar:1348362, lxrp
Also known as LEXARIA BIOSCIENCE CORP., LEXARIA CORP., Lexaria Bioscience Corp, Lexaria Bioscience Corp., Lexaria Corp.